NCT04079166
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04079166
Title SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Scancell Ltd
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR

Facility Status City State Zip Country Details
Cambridge University Hospitals NHS Foundation Trust Cambridge United Kingdom Details
Velindre University NHS Trust Cardiff United Kingdom Details
The Leeds Teaching Hospitals NHS Trust Leeds United Kingdom Details
Guy's & St Thomas' NHS Foundation Trust London United Kingdom Details
Royal Free London NHS Foundation Trust London United Kingdom Details
The Royal Marsden NHS Foundation Trust London United Kingdom Details
The Christie NHS Foundation Trust Manchester United Kingdom Details
East and North Hertfordshire NHS Trust Northwood United Kingdom Details
Nottingham University Hospitals NHS Trust Nottingham United Kingdom Details
Oxford University Hospital NHS Foundation Trust Oxford United Kingdom Details
University Hospital Plymouth NHS Trust Plymouth United Kingdom Details
Lancashire Teaching Hospitals NHS Foundation Trust Preston United Kingdom Details
Sheffield Teaching Hospital NHS Foundation Trust Sheffield United Kingdom Details
University Hospital Southampton NHS Foundation Trust Southampton United Kingdom Details
Somerset NHS Foundation Trust Taunton United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field